Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027497 (
nausea
)
23,468
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Twenty consecutive patients with chronic renal failure (CRF) and 20 control patients received subarachnoid anaesthesia with 3 ml of 0.75% bupivacaine plain for surgery in the lower abdomen. Sensory analgesia (onset) developed significantly more rapidly in the CRF patients: maximum segmental level of pin-prick analgesia was reached in an average of 21 min in the CRF patients and in 35 min in the control patients. An observed tendency to acidosis and a possible reduced intrathecal space in the uraemic patients may account for the more rapid blockade. The mean spread of the sensory block in CRF patients (T4) was two segments higher than that in the control patients, but because of marked inter-individual variation this difference cannot be considered clinically important. Three CRF patients and two control patients had insufficient analgesia for surgery. In the CRF patients, both sensory and motor blockades were of shorter duration than in the control patients. The incidence of complaints of
nausea
and
backache
was similar in the groups. One control patient had a headache.
...
PMID:Subarachnoid anaesthesia with 0.75% bupivacaine in patients with chronic renal failure. 370 97
A questionnaire survey of 84 Chinese nurses was carried out to assess the presence of premenstrual syndrome. More than half of the respondents reported emotional changes and
backache
premenstrually. There were significant associations between
nausea
and breast changes, irritability and depression, body and skin changes, finally between
backache
and the 3 symptoms of irritability, headache and the necessity to take time off work.
...
PMID:The premenstrual syndrome in Chinese. 386 87
In 100 patients with irritable bowel syndrome a wide variety of non-gastrointestinal symptoms were significantly more common than in a group of 100 age, sex, and social class matched controls. Nocturia, frequency and urgency of micturition, incomplete bladder emptying,
back pain
, an unpleasant taste in the mouth, a constant feeling of tiredness and in women dyspareunia were particularly prominent (p less than 0.001). With reference to non-colonic gastrointestinal symptoms
nausea
, vomiting, dysphagia and early satiety were very common (p less than 0.0001). This symptom diversity was observed irrespective of whether the patient had a psychiatric disorder or not. Patients smoked more than controls (p = 0.02) drank more caffeine containing drinks (p = 0.03) and 26% had taken at least one week off work in the previous 12 months. Thirty three per cent of patients had a family history of irritable bowel syndrome. Cognisance of these diverse symptoms may prevent referral to the wrong medical specialty and inappropriate investigation. They may also be indicative of a much more diffuse disorder of smooth muscle than has previously been appreciated.
...
PMID:Non-colonic features of irritable bowel syndrome. 394 35
Ten healthy normal volunteers received an intravenous infusion of erythromycin lactobionate over 60 min to a total dose of 800 mg (n = 9), and 524 mg (n = 1). Blood samples were collected at 10 min intervals for 100 min and gastric contents aspirated, via a nasogastric tube, from pre-dose to 105 min after start of infusion. Incidence and severity of three gastrointestinal symptoms (
nausea
, stomach discomfort and feelings of hunger), two CNS symptoms (dizziness and faintness) and a 'control' symptom (
back pain
) were measured using 100 mm visual analogue scales. Rate of infusion and plasma erythromycin concentration correlated with
nausea
(P less than 0.001) and stomach discomfort (P less than 0.001); plasma erythromycin concentration was also correlated with dizziness (P less than 0.05). Concentrations of active erythromycin in the aspirate were pH dependent. In one subject the concentration of erythromycin in the aspirate exceeded that in the plasma by 100 fold. Bile staining of samples containing the highest levels of microbiologically active erythromycin makes the origin of the erythromycin in these samples uncertain.
...
PMID:Gastrointestinal side effects after intravenous erythromycin lactobionate. 396 30
Seventy-nine patients underwent lumbar myelography on an outpatient basis, with a low (3.75 g) dose of metrizamide as the radiocontrast agent and a 25-gauge spinal needle used for lumbar puncture. No patient experienced significant neurotoxicity following the examination; 70.8% (56 of 79) experienced minimal (23%) or no (48%) side effects. Three patients (3.8%) were admitted to the hospital for management of common side effects (headache,
nausea
/vomiting,
back pain
). We obtained postmyelographic computed tomographic scans on 96% (76 of 79) of the patients. Our initial results suggest that outpatient lumbar myelography is safe and can be performed with a very acceptable incidence of side effects.
...
PMID:Outpatient lumbar myelography. Initial results in 79 examinations using a low-dose metrizamide technique. 404 46
The effect of norethisterone enanthate on clinical and biochemical parameters was studied in 9 normal women aged 21-29 years. Blood samples were taken before and 2, 6, 10, and 14 weeks after injection. Significant changes in serum proteins were observed, as was a significant increase in blood coagulability. Serum triglycerides were significantly lower. Thrombosis and effects on adrenal cortex function and on glucose tolerance were not observed. Side effects included breakthrough bleeding,
nausea
, headache, fatigue, nervousness, breast tension, and
backache
.
...
PMID:[Norethisterone enanthate. Studies during the use of a long-acting parenteral contraceptive]. 535 31
Iopamidol is a new, nonionic, water-soluble contrast material currently undergoing clinical trials for intravascular and intrathecal use in Europe and the United States. In this study, 12 patients underwent lumbar myelography with this agent. For each subject, up to 12 mL of iopamidol (at 200 mg I/mL) was employed. The myelograms obtained were highly satisfactory. No serious adverse reactions were observed. The most common side effect--headache--occurred in seven patients. However, six of the seven headaches were mild and transient, and did not require treatment.
Nausea
occurred in two patients,
back pain
in two patients, hypotension and hypertension each in one patient. All of these reactions were mild and self-limited. Iopamidol appears to be a safe and conveniently used agent for lumbar myelography.
...
PMID:Iopamidol in lumbar myelography. 622 4
Seventy out-patients with acute
back pain
participated in a double-blind comparative trial of the clinical efficacy and tolerance of orally administered meptazinol and diflunisal. Half of the patients received 200 mg meptazinol or 250 mg diflunisal 4-times daily for up to 3 weeks, depending on the duration of pain. Patients were examined 4 times at 1-week intervals for their capability to do daily tasks, for their capacity for forward bending, thoraco-lumbar torsion, straight leg raising, static hip flexion and sit-ups, and for subjective assessment of pain. Side-effects were recorded on a questionnaire. Both treatments produced marked improvement in most of the parameters assessed, often within the first week and, overall, the results were similar with the two drugs. Few side-effects were reported and those that were recorded were slight and similar in incidence apart from
nausea
in 5 meptazinol-treated patients and smarting and burning on urination in 2 patients receiving diflunisal.
...
PMID:Double-blind parallel study of meptazinol versus diflunisal in the treatment of lumbago. 623 53
Recombinant interferon-gamma was given to patients with tumours by a six-hour intravenous infusion using a portable mini-pump, to assess the side-effects of the drug. At present, 11 patients have been treated; 2 adenocarcinoma of the ovary, 3 squamous carcinoma of the bronchus, 1 adenocarcinoma of the breast, 1 adenocarcinoma of the stomach, 1 Hodgkin's lymphoma, 1 case of two primaries, adenocarcinoma of the breast and ovary, and 1 adenocarcinoma of unknown origin. Two patients received 1 X 10(6) units/m2/infusion, four received 3 X 10(6) U/m2/inf., three received 6 X 10(6) U/m2/inf. and two received 9 X 10(6) U/m2/inf. Two further dose levels will be used in the future; 27 and 51 X 10(6) U/m2/inf. Three 6-hour infusions a week were given for a four week period. The major side-effects of gamma-interferon were dose-related pyrexia with rigors to which there was no tachyphylaxis, acute and chronic tiredness,
nausea
with or without vomiting, headache,
backache
and myalgia. There was also a dose-dependent immediate but mild and transient decrease in the total white cell count. All effects have been transient, and none have been severe. We have also noticed that intravenous infusions by mini-pumps are tolerated far better by the patients than conventional drip systems, and we feel mini-pumps are the ideal way to give intravenous infusions.
...
PMID:A phase 1 study of recombinant interferon-gamma given intravenously by portable mini-pump: a preliminary report. 624 30
The relationship between symptoms reported during the first two cycles of oral contraceptive use and subsequent discontinuation was studied using data from a comparative clinical trial of two oral contraceptives (standard dose and low dose) in Sri Lanka. Among 24 symptoms considered, the most commonly reported were headache,
nausea
, irritability, dizziness, tiredness, intermenstrual spotting/bleeding,
backache
, abdominal pain, vomiting, and hair loss. Headache,
nausea
, vomiting, and dizziness were closely associated with each other and strongly predictive of discontinuation for both drugs. No other symptoms were consistently associated with each other or with subsequent discontinuation. Intermenstrual spotting/bleeding was associated with later discontinuation of the standard dose preparation, but not the lower dose preparation.
...
PMID:Early symptoms and discontinuation among users of oral contraceptives in Sri Lanka. 639 60
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>